Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

Abstract

Neratinib was the most effective HER2-targeted TKI against HER2-amplified, -mutant, and EGFR-mutant cell lines. This analysis revealed novel resistance mechanisms that may be exploited using combinatorial strategies.